Andrew G. Reaume PhD, MBA

Dr. Reaume has been responsible for building a robust, proprietary, clinical candidate pipeline for Melior while simultaneously attracting the partnership of many of the leading global pharmaceutical companies through Melior’s capabilities within vivo profiling.

Dr. Reaume was previously a Senior Business Analyst at Pfizer, Inc. in the department of genomics and proteomic sciences. While at Pfizer, he conceived of the idea to create a platform for comprehensively characterizing (phenotyping) genetically modified mice. He subsequently spearheaded the initiative to build it with a third party collaborator by working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company.

From 1993 to 1999 Dr. Reaume worked in R&D at Cephalon where he was principally involved in creating animal models of neurodegenerative disease. In addition to Dr. Reaume’s research activities, at Cephalon he identified and helped coordinate in-licensing opportunities. In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management. He received his Ph.D. in genetics from the University of Connecticut in 1990.